Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

RAPT Therapeutics, Inc.

$58.02

+0.04 (+0.07%)

D 34Pipeline Score Richly Valued Pharma · Clinical
Market Cap
1.61 B
EPS
-11.07
P/E Ratio
-
Value Trade
645.21 M
SEC Financials
Q3 2025

  • Dilution Risk

    25%

  • R&D Expenses

    12.03 M

  • Total Assets

    165.74 M

  • Total Liabilities

    13.76 M

  • Equity

    151.98 M

  • D/E Ratio

    12,345

0.21 %
Week
0.66 %
1 Month
84.07 %
3 Month
391.28 %
6 Month
-62.75 %
5 Year
-40.8 %
All Time
Cash Data
Stable

  • Cash Position

    157.34 M

  • Monthly Burn

    6.46 M

  • Runway

    16.2 mo

  • Burn Trend

    Stable

  • SEC Filing

    Nov 6, 2025
Overview
Volume
11.13 M
52 Week Range
5.67 - 58.02
% held by Insiders
48.8 %
% held by Institutions
66.35 %
Enterprise Value
1.45 B
Total Shares
16.51 M
Short %
22.48 %
Float Shares
5.96 M
Company Description
Founded:2015

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
Phase 2 Readout example
RPT-904 food allergy
Phase 2b
—

Subscribe to access the data.

Small Molecules
Digestive System
RPT-904 food allergy
Phase 2b
—

Subscribe to access the data.

Small Molecules
Digestive System
RPT-904 food allergy
Phase 2b
—

Subscribe to access the data.

Small Molecules
Digestive System
Unlock Upcoming Catalyst data
Unlock the full Catalyst Timeline
Past FDA Catalysts & PDUFA Decisions
Date Drug Catalyst Stage Outcome Reaction Event Move % Best Trade %
2025-10-27
ozureprubart (formerly RPT904)
phase 2b data readout
Phase 2b
—
–
–
–
2025-10-27
ozureprubart (formerly RPT904)
phase 2b data readout
Phase 2b
—
–
–
–
2025-10-27
ozureprubart (formerly RPT904)
phase 2b data readout
Phase 2b
—
–
–
–
Unlock Historical Catalyst data
Drug Pipeline Intelligence
D34
Pipeline Score
$188M
Pipeline Value
Richly Valued
Valuation Signal
4
Drugs Scored
0.1x
rNPV / MCap
Top 43%
Micro Cap
(rank 521 of 912)
Percentile Rank
RAPT Therapeutics, Inc. faces pipeline headwinds (34/100), with $576M risk-adjusted pipeline value, led by RPT193 in Atopic Dermatitis (Phase 1).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
RPT193
Small molecule		Atopic DermatitisPhase 1NCT0427151410% $293M COMPLETED 103 - -Apr 26, 2021 -Sep 30, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
RPT904
Chronic Spontaneous Urticaria
Phase 2
2025-10-20

mean baseline UAS7 scores: Q8W 28.7 (±7.2), Q12W 28.9 (±6.6), Q4W 28.8 (±7.9)

Read More

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Read More
RPT904
Chronic Spontaneous Urticaria
Phase 2
2025-10-20

mean baseline UAS7 scores: Q8W 28.7 (±7.2), Q12W 28.9 (±6.6), Q4W 28.8 (±7.9)

Read More

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Read More
RPT904
Chronic Spontaneous Urticaria
Phase 2
2025-10-20

mean baseline UAS7 scores: Q8W 28.7 (±7.2), Q12W 28.9 (±6.6), Q4W 28.8 (±7.9)

Read More

RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Read More
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in RAPT
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
RAPT Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
Competitive Position
How RAPT ranks across every disease it competes in
Competitive Position is a premium feature
See how RAPT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial